- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal: Inhibitory effect of edaravone on systemic inflammation and local damage in skeletal muscles following long-term ischemia to murine hind limb. (Pubmed Central) - Jul 7, 2020
Skeletal muscles exhibited prominent injury of myofibers at 12 h after I/R injury, with clear upregulation of plasma TNF-α expression and histologic evidence of tubular dysfunction of the kidneys. Plasma TNF-α levels declined and histologic renal damage was ameliorated in edaravone-treated mice, but treatment did not protect skeletal muscle following ischemia for 4 h. Nonetheless, compared with group S, expression of the apoptosis marker caspase 3/7 was significantly inhibited in the skeletal hind limb muscles of Ed-group mice affected by reperfusion injury following ischemia for 4 h. The present study demonstrated that edaravone is a potentially useful drug for systemic or local treatment of reperfusion injury resulting from long-term ischemia.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Journal, IO Biomarker: Edaravone reduces oxidative stress and intestinal cell apoptosis after burn through up-regulating miR-320 expression. (Pubmed Central) - Jul 7, 2020
Plasma TNF-α levels declined and histologic renal damage was ameliorated in edaravone-treated mice, but treatment did not protect skeletal muscle following ischemia for 4 h. Nonetheless, compared with group S, expression of the apoptosis marker caspase 3/7 was significantly inhibited in the skeletal hind limb muscles of Ed-group mice affected by reperfusion injury following ischemia for 4 h. The present study demonstrated that edaravone is a potentially useful drug for systemic or local treatment of reperfusion injury resulting from long-term ischemia. ED regulates Akt/Bad/Caspase signaling cascade to reduce apoptosis and oxidative stress through up-regulating miR-320 expression and down-regulating PTEN expression, thus protecting the intestinal mucosal barrier of rats from burn injury.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
[VIRTUAL] The Effect of Edaravone on Respiratory Function in Amyotrophic Lateral Sclerosis (ALS) (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_4120;
In contrast with current literature, pre and post-edaravone treatment measurements show no difference in the rate of change of FVC as well as the ALSFRS-R respiratory scores. No patients in our cohort met all eligibility criteria described in the phase III trial which led to FDA approval, raising concerns that edaravone may not be effective in a broadly inclusive patient population.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal: Edaravone has a protective role in a mouse model of pulmonary oxygen toxicity (Pubmed Central) - Jul 1, 2020
No patients in our cohort met all eligibility criteria described in the phase III trial which led to FDA approval, raising concerns that edaravone may not be effective in a broadly inclusive patient population. These results showed that edaravone treatment had a protective role in pulmonary oxygen toxicity through curbing inflammation and apoptosis.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Review, Journal: Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs. (Pubmed Central) - Jun 27, 2020
Molecules can be nanoengineered to carry out multiple specific functions such as to cross the BBB, target specific cell or signaling pathway, respond to endogenous stimuli, and act as a vehicle for gene delivery, support nerve regeneration and cell survival. In present review, the role of nanocarrier systems such as liposomes, micelles, solid lipid nanoparticles (SLNPs), dendrimers, and nanoemulsions for delivery of various neurotherapeutic agents has been discussed, besides this, their mechanism of action, and nanoformulation of different neuroprotective agents like curcumin, edaravone, nerve growth factors in CNS disorders like Alzheimer's, Parkinsonism, epilepsy, stroke, and brain tumors has been reviewed.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal: Effects of Edaravone on Nitric Oxide, Hydroxyl Radicals and Neuronal Nitric Oxide Synthase During Cerebral Ischemia and Reperfusion in Mice. (Pubmed Central) - Jun 25, 2020
In present review, the role of nanocarrier systems such as liposomes, micelles, solid lipid nanoparticles (SLNPs), dendrimers, and nanoemulsions for delivery of various neurotherapeutic agents has been discussed, besides this, their mechanism of action, and nanoformulation of different neuroprotective agents like curcumin, edaravone, nerve growth factors in CNS disorders like Alzheimer's, Parkinsonism, epilepsy, stroke, and brain tumors has been reviewed. These in vivo data indicate that edaravone may have a neuroprotective effect by reducing levels of OH metabolites, increasing NO production and decreasing nNOS expression in brain cells.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Journal: Renoprotective effect of edaravone in acute limb ischemia/reperfusion injury. (Pubmed Central) - Jun 23, 2020
Edaravone ameliorated renal injury caused by lower-limb ischemia/reperfusion. Therefore, it can be used to ameliorate acute ischemia/reperfusion injury during aortic and peripheral vascular surgery.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal: Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro. (Pubmed Central) - Jun 18, 2020
Although the edaravone treatment had no effects on the intracellular levels of Cys and GSH, both of which remained low in Hepa 1-6 cells under conditions of cystine deprivation, the causative factors for ferroptosis, including ferrous iron and lipid peroxide levels, were significantly suppressed. Collectively, these results indicate that radical species produced at the initial stage of the cytocidal process under Cys-deprived conditions trigger ferroptosis and scavenging these radicals by edaravone represents a promising treatment.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Journal: N-Acetyl cysteine prevents activities of STAT3 inhibitors, Stattic and BP-1-102 independently of its antioxidant properties. (Pubmed Central) - Jun 14, 2020
Collectively, these results indicate that radical species produced at the initial stage of the cytocidal process under Cys-deprived conditions trigger ferroptosis and scavenging these radicals by edaravone represents a promising treatment. NAC antagonizes the activities of Stattic and BP-1-102, which inhibit STAT3 activation by interacting with cysteine residues in STAT3.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Clinical, Journal: Recent treatment patterns and variations for pediatric acute encephalopathy in Japan. (Pubmed Central) - Jun 4, 2020
We provided novel insights into the recent trends in treatments for pediatric acute encephalopathy. Therapeutic strategies varied between hospitals, suggesting the importance of pursuing evidence-based treatment strategy and promoting standardized practices to pediatric acute encephalopathy.
- |||||||||| riluzole / Generic mfg., Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Journal: What Is in the Literature. (Pubmed Central) - May 23, 2020
Major efforts to make trials more sensitive are being considered. There are a number of articles with helpful and practical findings for the diagnosis and management of ALS.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal, IO Biomarker: Edaravone protects rat astrocytes from oxidative or neurotoxic inflammatory insults by restoring Akt/Bcl-2/Caspase-3 signaling axis. (Pubmed Central) - May 10, 2020
In addition, edaravone mitigated LPS-induced morphological changes in astrocytes and alleviated the inflammatory activation and expression of TNF-α, IL-1β, IL-6 and NOS2. In summary, our data suggested that edavarone effectively protects astrocytes from oxidative stress or infectious insults, which may pave a new avenue for its application in preclinical research and human disease therapeutics.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Clinical, Journal: Clinical trials in amyotrophic lateral sclerosis. (Pubmed Central) - May 7, 2020
For many decades there has been regular disappointment with the results of clinical trials. With the innovations in trial design and advances in our basic understanding of the biology of ALS, the prospects for a step change in treatments for people affected by ALS are strong.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Journal: Edaravone and MAPK pathway: the key role of gut permeability. (Pubmed Central) - May 6, 2020
These findings demonstrated that edaravone protected neurons against ketamine-induced apoptosis by diminishing oxidative stress and activating PI3K/Akt signal pathway. No abstract available
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Biomarker, Journal: The protective effect of edaravone on memory impairment induced by chronic sleep deprivation. (Pubmed Central) - Apr 26, 2020
Additionally, edaravone prevented decreases in hippocampal GPx, catalase, GSH/GSSG ratio and normalized increases in GSSG levels, which were impaired by SD model. In conclusion, current result showed a protective effect of edaravone administration against SD induction that could be related to edaravone's ability to normalizing mechanisms related to oxidative balance.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Clinical, P4 data, Journal: Early post-marketing experience with edaravone in an unselected group of patients with ALS. (Pubmed Central) - Apr 19, 2020
Results of our study comparing edaravone treated and untreated patients in a real-life setting showed no differences in the rate of monthly decline of ALSFRS-R, in line with previous reports in ALS patients not treated with edaravone, and a previous clinical trial. Our findings might suggest that edaravone is not effective in unselected ALS patients.
- |||||||||| Review, Journal, Adverse events: Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers. (Pubmed Central) - Apr 19, 2020
EDA is a mild antiproliferative agent but has been found to enhance significantly the anticancer and antimetastatic activities of irinotecan in a colon cancer model...Notably EDA can reduce the renal dysfunction induced by cisplatin, the neurotoxicity of cyclophosphamide and the cardiotoxicity of doxorubicin...Therefore, EDA could also be useful to reduce specific side effects of immuno-therapy. Collectively, the information suggests that the medical use of EDA, a drug with a proven safety after 18 years of use in brain-related Human diseases, could be extended to cancer-related conditions.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Clinical, Retrospective data, Journal: Long-term Edaravone Efficacy in ALS: Post-hoc Analyses of Study 19 (MCI186-19). (Pubmed Central) - Apr 14, 2020
Collectively, the information suggests that the medical use of EDA, a drug with a proven safety after 18 years of use in brain-related Human diseases, could be extended to cancer-related conditions. Compared with placebo, these analyses suggest that edaravone is beneficial in ALS patients even after 6 months of receiving placebo and efficacy is maintained for up to 1 year.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
[VIRTUAL] NEUROPROTECTIVE EFFICACY OF EDARAVONE AGAINST ARSENIC-INDUCED BEHAVIORAL AND NEUROCHEMICAL DEFICITS IN RATS. () - Apr 7, 2020 - Abstract #AATADPD2020AAT_ADPD_1098;
However, chronic treatment with edaravone (10 mg/kg) significantly ameliorated the arsenic-induced behavioral deficits and neurochemical anomalies. Conclusions Thus, our current study clearly showed that edaravone confers neuroprotection against arsenic-induced memory impairment and anxiety-like behavior which may be attributed to the inhibition of oxidative-nitrosative stress and amelioration of cholinergic and mitochondrial functions.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Journal, IO Biomarker: Improvement in mitochondrial function underlies the effects of ANNAO tablets on attenuating cerebral ischemia-reperfusion injuries. (Pubmed Central) - Mar 24, 2020
This finding displayed that DG-15 had dual functions of neuroprotection and angiogenesis, which provided further insight into designing agent for the application in treatment of ischemic stroke. The obtained data demonstrated that ANNAO tablets exhibited an obvious anti-cerebral ischemia-reperfusion effect, which could be attributed to the improvement of mitochondrial quality control.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Journal: Edaravone for ALS: More Evidence for Long-Term Benefit. (Pubmed Central) - Mar 24, 2020
The obtained data demonstrated that ANNAO tablets exhibited an obvious anti-cerebral ischemia-reperfusion effect, which could be attributed to the improvement of mitochondrial quality control. No abstract available
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
The Effect of Edaravone on Respiratory Function in Amyotrophic Lateral Sclerosis (ALS) (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) - Mar 15, 2020 - Abstract #ATS2020ATS_6554;
In contrast with current literature, pre and post-edaravone treatment measurements show no difference in the rate of change of FVC as well as the ALSFRS-R respiratory scores. No patients in our cohort met all eligibility criteria described in the phase III trial which led to FDA approval, raising concerns that edaravone may not be effective in a broadly inclusive patient population.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Clinical, Journal, Real-World Evidence: Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke. (Pubmed Central) - Feb 22, 2020
Results- After adjusting for potential confounders, the improvement in NIHSS score from admission to discharge was greater in the edaravone-treated group than in the no edaravone group for all ischemic stroke subtypes (mean [95% CI] difference in ΔNIHSS: -0.46 [-0.75 to -0.16] for large-artery atherosclerosis, -0.64 [-1.09 to -0.2] for cardioembolism, and -0.25 [-0.4 to -0.09] for small-vessel occlusion). Conclusions- For any ischemic stroke subtype, edaravone use (compared with no use) was associated with a greater improvement in neurological symptoms, although the difference was small (<1 point NIHSS) and of limited clinical significance.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe, apixaban / Generic mfg.
Clinical, Journal: A case of autoimmune hemolytic anemia diagnosed by occurrence of cardioembolic stroke (Pubmed Central) - Feb 21, 2020
She had taken apixaban due to her non-valvular atrial fibrillation...Intravenous infusion of heparin and edaravone was initiated, and her neurological symptoms improved...It should be noted that autoimmune hemolytic anemia can develop as thrombotic disease. In the present case, autoimmune hemolytic anemia was diagnosed based on the development of cardioembolic stroke.
- |||||||||| Soliris (eculizumab) / Alexion Pharma, efgartigimod IV (ARGX-113 IV) / argenx, Broteio
Review, Journal: Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. (Pubmed Central) - Feb 15, 2020
Efgartigimod showed great promise in a phase 2 safety and efficacy trial in the treatment of stable generalized myasthenia gravis...While there are some newer immunotherapies available, few have been studied in the acute setting. However, with the advent of new immunotherapies and biologics, changes in these approaches may be on the horizon.
- |||||||||| cyclophosphamide oral / Generic mfg., Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal: Protective effect of edaravone on cyclophoshamide induced oxidative stress and neurotoxicity in rats. (Pubmed Central) - Feb 14, 2020
However, with the advent of new immunotherapies and biologics, changes in these approaches may be on the horizon. This study suggests that co-administration of edaravone with cyclophosphamide may be a useful intriguing therapeutic approach to overcome cyclophosphamide induced neurotoxicity.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal: Edaravone Administration Confers Neuroprotection after Experimental Intracerebral Hemorrhage in Rats via NLRP3 Suppression. (Pubmed Central) - Feb 14, 2020
This study suggests that co-administration of edaravone with cyclophosphamide may be a useful intriguing therapeutic approach to overcome cyclophosphamide induced neurotoxicity. The present study demonstrated that edaravone conducted neuroprotection after ICH partially via suppressing NF-κB-dependent NLRP3 in microglia, which contributed a novel evidence for clinic usage of edaravone after ICH.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Preclinical, Journal: Edaravone attenuates experimental asthma in mice through induction of HO-1 and the Keap1/Nrf2 pathway. (Pubmed Central) - Feb 6, 2020
Taken together, the results of the present study show that Eda exerts anti-inflammatory and antioxidative effects, which suggests a potential use for Eda in reduction of asthma severity. The activated Keap1/Nrf2 pathway and HO-1 may be involved in the anti-asthmatic effect of Eda.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Journal: Paraquat: The Poison Potion. (Pubmed Central) - Feb 6, 2020
Paraquat: The Poison Potion. Indian J Crit Care Med 2019;23(Suppl 4):S263-S266.
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe
Biomarker, New trial: Radicava (clinicaltrials.gov) - Feb 6, 2020
P, N=300, Recruiting,
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe, edaravone (MT-1186) / Mitsubishi Tanabe
Radicava/Edaravone Findings in Biomarkers from ALS (REFINE ALS): Interim Analysis () - Feb 3, 2020 - Abstract #AAN2020AAN_5138;
The data from this RWE report are expected to be helpful for clinicians who are considering using Radicava® therapy with their ALS patients. The findings will help to further the understanding of the pharmacodynamic effect of edaravone on selected biomarkers relevant to disease mechanisms and possible mode of drug activity.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway. (Pubmed Central) - Jan 31, 2020
Dox produces excess ROS in the mitochondria, thereby weakens the MMP, opens mPTP, activates the ROS-induced ROS release mechanism, induces ROS burst, and leads to mitochondrial dysfunction, which in turn damages VE. Therefore, interrupting any step of the cycles, as mentioned above can end the related vicious cycle and prevent the occurrence and development of injury.
|
